obinutuzumab,venetoclax,chlorambucil
roche,abbvie
['cll14', 'cll']
#cll #eha2023 al-sawaf. 6yr fuo of cll14 trial
mva predictors of response tp53, ighv, bulk
mpfs 76m, os survival curves separate
mrd: 25% of available samples are mrd- at 5yr. mrd(-4) predictive of pfs and os, as good as 10e-6. 